acute vomit aspiration in a man with acute large intestine obstruction (severe megacolon) and clozapine-induced intestinal hypomotility
AI-generated summary
Stephen Michael Kell, a 35-year-old man with treatment-resistant schizophrenia, died at Graylands Hospital from acute vomit aspiration in the setting of acute large bowel obstruction and clozapine-induced gastrointestinal hypomotility. Despite appropriate psychiatric care and clozapine treatment per 2015 guidelines, a serious medication side effect—gastrointestinal hypomotility causing severe megacolon—was not widely recognised at that time. The coroner found his treatment appropriate but highlighted that clozapine-induced gastrointestinal hypomotility is now known to carry higher mortality than agranulocytosis. Key clinical lessons: gastrointestinal monitoring for clozapine patients is essential; symptoms such as vomiting or bowel changes warrant urgent assessment; and clinicians should maintain high suspicion for gastrointestinal complications rather than attributing symptoms solely to suspected drug use. Updated guidelines and product information now emphasise this risk.
AI-generated summary and tagging — may contain inaccuracies; refer to original finding for legal purposes. Report an inaccuracy.
Specialties
psychiatrygastroenterologytoxicologyforensic medicineemergency medicine
chronic treatment-resistant paranoid schizophreniaacute large intestine obstructionsevere megacolonclozapine-induced gastrointestinal hypomotilityconstipationcirrhosis of the liverepilepsyhypothyroidismhypertensionacute vomit aspirationasystole
Department of Health should amend its guidelines for the Safe and Quality Use of Clozapine Therapy in the Western Australian Health System to include reference to clozapine-induced gastrointestinal hypomotility as a serious side effect and recommend gastrointestinal monitoring in accordance with draft Guidelines for Managing Specific High Risk Medications Relevant to the Organisation
Pfizer Australia and Mylan Australia, in consultation with the Therapeutic Goods Administration, should consider highlighting the risk of clozapine-induced gastrointestinal hypomotility in the boxed warning that appears at the beginning of their Product Information for Clopine and Clozaril, and ensure it appears in MIMS Full Prescribing Information and Consumer Medicine Information
This page reproduces or summarises information from publicly available findings published by Australian coroners' courts. Coronial is an independent educational resource and is not affiliated with, endorsed by, or acting on behalf of any coronial court or government body.
Content may be incomplete, reformatted, or summarised. Some material may have been redacted or restricted by court order or privacy requirements. Always refer to the original court publication for the authoritative record.
Copyright in original materials remains with the relevant government jurisdiction. AI-generated summaries and tagging are for educational purposes only, may contain inaccuracies, and must not be treated as legal documents. We welcome feedback for correction — report an inaccuracy here.